Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Investor Presentation (August 2026)
43 slides from Syndax Pharmaceuticals's investor presentation, August 2026
Slide 1: Corporate Presentation
Corporate Presentation August 2026
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Syndax is delivering for patients and driving substantial long-term value
Syndax is delivering for patients and driving substantial long-term value TRACK RECORD WORLD-CLASS R&D DEEP AND GROWING SOLID FINANCIAL OF SUCCESS CAPABILITIES PIPELINE POSITION Proven ability to translate Fully integrated biotech Robust late- and early- Driving towards scientific discoveries into w
Slide 4: Advancing the standard of care for R/R NPM1m AML and KMT2Ar acute leukemia and chronic GVHD
Advancing the standard of care for R/R NPM1m AML and KMT2Ar acute leukemia and chronic GVHD with two first- and best-in-class medicines First and only menin inhibitor First and only CSF-1R-blocking with multiple indications antibody approved in R/R cGVHD Revuforj® (revumenib) and Niktimvo (axatilima
Slide 5: Strong 2Q26 results with multiple drivers for sustainable growth
Strong 2Q26 results with multiple drivers for sustainable growth • $55M in Revuforj net revenue (+91% y/y), highlighting leadership in menin inhibition, robust demand in NPM1 and KMT2A, and an increasing average duration of therapy ROBUST 2Q26 COMMERCIAL DEMAND • $60M in Niktimvo net revenue (+67% y
Slide 6: Revuforj (revumenib)
Revuforj® (revumenib) 6
Slide 7: Revuforj is FDA-approved for multiple patient subtypes
REVUFORJ IS FDA-APPROVED FOR MULTIPLE PATIENT SUBTYPES First and only menin inhibitor approved in adults & children ≥1 year of age with: R/R acute leukemia with KMT2A translocation R/R AML with NPM1 mutation Revuforj is FDA approved for the treatment of R/R acute leukemia with a KMT2A translocation
Slide 8: Strong 2Q26 Revuforj results with sixth consecutive quarter of double-digit growth
Strong 2Q26 Revuforj results with sixth consecutive quarter of double-digit net revenue and prescription growth 2Q26 Revuforj results Quarterly results Net revenue Approx. TRx $54.7M ~1,500 $60 $55M net revenue total prescriptions $49M $50 91% growth vs. 2Q25 ~121% growth vs. 2Q25 $44M 1,500 12% gro
Slide 9: Strong fundamentals in place to drive Revuforj growth
Strong fundamentals in place to drive Revuforj growth NEW PATIENT TREATMENT MARKET STARTS X DURATION = OPPORTUNITY • Opportunity to address ~6.5K R/R • Increasing average treatment duration • Comprehensive clinical patients annually: driven by evolving clinical practice development program underway
Slide 10: Revuforj is positioned for success with an outstanding commercial foundation
Revuforj is positioned for success with an outstanding commercial foundation Broad and expanding prescriber base Excellent payer coverage with no meaningful barriers to access 88% >580 98% of Tier 1+2 total accounts accounts activated (+11% q/q growth) of all covered lives with formulary coverage fo
Slide 11: Revuforj development program targets $5B+ U.S. market opportunity
Revuforj development program targets $5B+ U.S. market opportunity across R/R and 1L acute leukemia With the largest addressable $5B+ TAM across R/R and 1L population and extended U.S. Market Opportunity ($ B) treatment durations, Revuforj is tracking well above launch benchmarks set by other mutatio
Slide 12: Syndax is positioned to be first to 1L AML with Revuforj
Syndax is positioned to be first to 1L AML with Revuforj, building on a long history of delivering landmark ‘firsts’ First to clinically First FDA approved First menin First to receive First to publish validate menin menin inhibitor inhibitor added to FDA approval in clinical data First to inhibitio
Slide 13: Niktimvo (axatilimab-csfr)
Niktimvo (axatilimab-csfr) 13
Slide 14: Niktimvo is poised to deliver on the promise of CSF-1R inhibition in cGVHD and beyond
Niktimvo is poised to deliver on the promise of CSF-1R inhibition in cGVHD and beyond Novel MoA in cGVHD to address inflammation and fibrosis Trials underway in 1L cGVHD & IPF to further unlock multi- First and only CSF-1R-blocking antibody billion-dollar opportunity FDA approved in ≥3L cGVHD CONFID
Slide 15: Strong Niktimvo 2Q26 results driven by robust demand
Strong Niktimvo 2Q26 results driven by robust demand $60.3M $18.1M >300 2Q26 net revenue 2Q26 collaboration 2Q26 new patients to INCY revenue to SNDX 67% growth vs. 2Q25 93% growth vs. 2Q25 ~5,750 2Q26 infusions 9% growth vs. 1Q26 13% growth vs. 1Q26 administered Performance reflects strong, consist
Slide 16: Niktimvo is positioned for continued growth and success in cGVHD
Niktimvo is positioned for continued growth and success in cGVHD Strong Adoption in 4L with Extended Tx Durations to Growing Use in 3L cGVHD Address Chronic Disease Approx. one-third of 3L+ cGVHD ~60-70% of patients stay on market within 1.5 years of launch therapy for at least 12 months Broad Presc
Slide 17: Initial Niktimvo indication represents a $2B U.S. market opportunity
Initial Niktimvo indication represents a $2B U.S. market opportunity, with substantial opportunities for label and geographic expansion ~17,000 U.S. cGVHD patients1 $5B+ TAM $2B TAM with initial Niktimvo indication ~6,500 currently treated 3L+ U.S. cGVHD patients Ongoing combo trials could support f
Slide 18: Advancing a robust and growing pipeline with a proven R&D engine
Advancing a robust and growing pipeline with a proven R&D engine 18
Slide 19: Syndax is built to deliver innovative therapies in areas of high unmet need
WORLD-CLASS R&D ORGANIZATION • Talented team with extensive experience developing novel medicines and building leading franchises • Trailblazers in menin, CSF-1R, and EGFR inhibition Syndax is built to PARTNERSHIPS WITH LEADING RESEARCHERS deliver innovative • New discoveries catalyzed by long-stand
Slide 20: A robust and growing pipeline of programs
Pre- FDA Asset Setting Ph 1 Ph 2 Ph 3 clinical approved A ROBUST AND R/R acute leukemia GROWING PIPELINE OF PROGRAMS 1L AML (with SOC drugs) Revumenib Post-HSCT maintenance Positioned to be the 1st MRD relapse to deliver pivotal 1L data Myelofibrosis for a menin inhibitor (proof-of-principle) R/R cG
Slide 21: Advancing our leadership in menin inhibition
Advancing our leadership in menin inhibition 21
Slide 22: Positioned to continue leading menin inhibition in acute leukemia and beyond
Positioned to continue leading menin inhibition in acute leukemia and beyond BROADEST INDICATION INTEGRATED EVIDENCE LIBRARY OF NEXT-GEN STRONG SCIENTIFIC & CLINICAL ACTIVITY GENERATION PLAN MENIN INHIBITORS PARTNERSHIPS • Only menin inhibitor • Rapidly growing body of • Internally developed • Colla
Slide 23: Syndax is pioneering menin inhibition across multiple acute leukemia settings and subtypes
Syndax is pioneering menin inhibition across multiple acute leukemia settings and subtypes, including NPM1m, KMT2Ar, and NUP98r MAINTENANCE & RELAPSED / FRONTLINE (1L) MRD RELAPSE REFRACTORY INELIGIBLE FOR IC (‘UNFIT’) ELIGIBLE FOR IC (‘FIT’) BEAT AML SNDX-708 + NCI trial INTERCEPT AUGMENT-101 Ph 1/
Slide 24: Recent medical meetings and publications highlight scientific leadership in menin inhibition
Recent medical meetings and publications highlight Syndax’s scientific leadership in menin inhibition June June June July Presented 4 revumenib Presented 12 revumenib Published first data for Published landmark abstracts, including an abstracts spanning an all-oral, menin-based preclinical data show
Slide 25: Following the science to unlock the full potential of menin inhibition
Following the science to unlock the full potential of menin inhibition KMT2Ar NPM1m NUP98r POST-HSCT MF BEYOND MAINTENANCE Disease Disease Disease Growing body of evidence shows revumenib has robust activity across • Emerging data highlights the potential multiple acute leukemia subtypes and setting
Slide 26: Leading menin inhibition into the future with a library of next-gen molecules
Leading menin inhibition into the future with a library of next-gen molecules plus the ability to leverage revumenib to de-risk development in new areas Library of internally SNDX-62122 developed next-gen next-generation menin inhibitors menin inhibitor • Molecules will be deployed in new areas, sta
Slide 27: Leveraging revumenib to inform and de-risk development of SNDX-62122 in MF
Leveraging revumenib to inform and de-risk development of SNDX-62122 in MF Anticipated path forward ✓ Publish Initiate Ph 1 of preclinical MF data Submit IND for Initiate revumenib SNDX-62122 in MF SNDX-62122 proof-of-principle in 2027, leveraging (next-gen menin MF trial in 4Q26 learnings with inhi
Slide 28: Phase 1/2 proof-of-principle trial of menin inhibition in MF expected to initiate in 4Q26
Phase 1/2 proof-of-principle trial of menin inhibition in MF expected to initiate in 4Q26 in partnership with the MPN-RC consortium The Myeloproliferative Neoplasm Research Consortium (MPN-RC) is a group of leading researchers from 15 institutions R/R MF following Newly diagnosed MF Key inclusion cr
Slide 29: Unlocking the potential of CSF-1R inhibition
Unlocking the potential of CSF-1R inhibition 29
Slide 30: Following the science to unlock the full potential of CSF-1R inhibition
Following the science to unlock the full potential of CSF-1R inhibition R/R cGVHD 1L cGVHD IPF BEYOND Pivotal trial showed robust Ongoing trials could Topline Ph 2 MAXPIRe Mechanism holds promise responses across all organs advance axa into 1L cGVHD, data expected 4Q26 across an array of diseases st
Slide 31: CSF1-dependent monocyte-derived alveolar macrophages as a promising new target in IPF
A growing body of evidence points to CSF1-dependent monocyte-derived alveolar macrophages as a promising new target in IPF Key discoveries: ➢ Monocyte-derived alveolar macrophages drive lung fibrosis ➢ Colony stimulating factor-1 receptor (CSF1R) signaling is a key regulator of monocytes and macroph
Slide 32: Development in IPF supported by lung responses observed in cGVHD
Axatilimab is a CSF1R-blocking Development in IPF supported by lung antibody targeting monocyte-derived responses observed in cGVHD alveolar macrophages in IPF • Blocking CSF-1R with axatilimab: • Among cGVHD pts with lung involvement who received axa o Reduces levels of circulating profibrotic and
Slide 33: Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF anticipated in 4Q26
Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF anticipated in 4Q26 Randomized, double-blind, placebo-controlled, multi-center international trial Key eligibility criteria: 26-week treatment • ≥40 yrs of age Axatilimab 0.3 mg/kg Q2W • HRCT confirming IPF diagnosis (n≈90) • FVC ≥45% of p
Slide 34: Expanding our pipeline into EGFRm NSCLC with SNDX-4321
Expanding our pipeline into EGFRm NSCLC with SNDX-4321 34
Slide 35: Allosteric inhibitors are increasingly reshaping the standard of care for difficult-to-treat cancers
Allosteric inhibitors are increasingly reshaping the standard of care for difficult-to-treat cancers Melanoma Chronic myeloid leukemia EGFRm NSCLC Trametinib (Mekinist) Asciminib (Scemblix) SNDX-4321 MEK1 BCR-ABL1 ATP EGFR SNDX-4321 Allosteric site allosteric site ATP ATP binding site site site Allo
Slide 36: Current and investigational therapies for EGFRm NSCLC primarily target the ATP-binding site
Current and investigational therapies for EGFRm NSCLC primarily target the ATP-binding site 3rd gen approved EGFRi ATP-site directed Allosteric inhibitors • Reduced benefit for patients EGFR with L858R, CNS metastases, Osimertinib Lazertinib or atypical activating mutations SNDX-4321 Syndax aims to
Slide 37: SNDX-4321 is a novel, mutant-selective, CNS-penetrant, allosteric EGFR inhibitor for NSCLC
SNDX-4321 is a novel, mutant-selective, CNS-penetrant, allosteric EGFR inhibitor for NSCLC • Novel approach to addressing patient populations EGFR with high unmet needs, such as those with L858R ATP site mutations, CNS metastases, atypical activating mutations, or acquired resistance to current drug
Slide 38: Corporate highlights and upcoming milestones
Corporate highlights and upcoming milestones 38
Slide 39: Strong financial position with growing revenue and a robust balance sheet
Strong financial position with growing revenue and a robust balance sheet On the road to profitability Financial Summary Three Months Ended ($ in millions) June 30 2026 2025 Product revenue, net 54.7 28.6 AS OF 30 JUN 2026: Collaboration revenue, net 18.1 9.4 $575.1M in cash and equivalents1 Total r
Slide 40: Well positioned for long-term growth with multiple blockbuster opportunities
Positioned to be 1st menin Phase 2 readouts in IPF and approved in 1L AML; peak annual 1L cGVHD in 4Q26 target new net revenue in excess of $2B multi-billion-dollar opportunities WELL POSITIONED FOR expected in the U.S. alone LONG-TERM GROWTH WITH MULTIPLE BLOCKBUSTER OPPORTUNITIES AND UPCOMING MILE
Slide 41: Multiple near-term catalysts and blockbuster opportunities
Multiple near-term catalysts and blockbuster opportunities Anticipated milestones Acute Leukemia • Advance global enrollment in pivotal 1L trials of revumenib • New 1L, maintenance, real-world, and R/R revumenib data in 2H26 + beyond Revuforj (revumenib) • Publish R/R NUP98r data in 4Q26 & SNDX-6212
Slide 42: Fueled by a passion for patients
FUELED BY A PASSION FOR PATIENTS 42
Slide 43: Slide 43
Syndax Pharmaceuticals — Investor Presentation (August 2026) on 6ix